Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Vaginal Oxytocin Gel for Postmenopausal Vaginal Atrophy
NCT06514586Phase 3Not yet recruiting
- Sponsor
- Oxagon
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
A Phase 3 trial of oxytocin nasal spray in vaginal atrophy, genitourinary syndrome of menopause (GSM), sponsored by Oxagon. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
vaginal atrophygenitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT06514586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514586.